6:24   ESMO 2025: key takeaways in head and neck cancer 1:26   Making optimal decisions in frontline treatment of CLL: fixed-duration vs continuous BTKi treatment 3:26   Updates to the ESMO guidelines for the treatment of mantle cell lymphoma 1:04   Can Venetoclax + Ibrutinib Match Continuous Ibrutinib in CLL? CLL17 Trial Non-Inferiority Data 1:03   Optimizing patient selection for combination therapies in oncology 3:12   CheckMate 9DW: HRQoL and efficacy in patients who discontinued due to adverse events 1:27   What are the treatment options for early onset colorectal cancer? 1:05   Challenges in integrating oncolytic virotherapy into clinical practice 6:08   LITESPARK-015: belzutifan in advanced pheochromocytoma and paraganglioma 0:59   Dr Leslie on Epcoritamab Plus Lenalidomide and Rituximab in Follicular Lymphoma 2:24   Overcoming barriers in treating pheochromocytomas and paragangliomas 1:06   Subgroup findings from the EV-302 trial of EV and pembrolizumab in la/mUC 1:47   Current care and biomarker needs in first-line metastatic urothelial cancer 1:52   Recent updates in second-line therapies for biliary tract cancer 1:33   RC48-C016: disitamab vedotin & toripalimab vs chemotherapy in HER2+ la/mUC 1:41   ASPEN: active surveillance vs surgery for small nonfunctioning PanNETs 2:10   Novel management strategies for melanoma beyond checkpoint inhibitors